---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-037533"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:29:46.913182+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lixte expands NKI/Oncode collaboration to study LB-100 + immunotherapy in additional cancers

## Summary
- Amendment 2 extends the Development Collaboration Agreement for two more years.
- New focus: drug synergies of LB-100 with immunotherapy plus synthetic lethal combinations in more cancer types.
- Prior two-year collaboration successfully identified LB-100 combinations for colon cancer.
- Parties include Netherlands Cancer Institute and Oncode Institute, with Prof. René Bernards on Lixte's board.
- No financial terms or milestones disclosed in the agreement.

## SEC filing metadata
- accession: 0001493152-23-037533
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/0001493152-23-037533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-037533
- JSON: https://secwatch.observer/filing/0001493152-23-037533.json
- Plain text: https://secwatch.observer/filing/0001493152-23-037533.txt

## Key facts
- Material Agreements
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Development Collaboration Agreement Amendment 2 with Netherlands Cancer Institute (NKI) and Oncode Institute valued at Amendment expands collaboration to study LB-100 with immunotherapy, extends agreement for two years (effective 2023-10-13).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Netherlands Cancer Institute (NKI) and Oncode Institute
  - Value: Amendment expands collaboration to study LB-100 with immunotherapy, extends agreement for two years
  - Effective: 2023-10-13
  source text: On October 13, 2023, the parties signed an amendment (“Amendment 2”) to expand the collaboration to study drug synergies of the Company’s lead compound, LB-100, with immunotherapy in various cancers. Under Amendment 2, the parties will seek to find synthetic lethal combinations in additional cancer types. Amendment 2 also extends the Collaboration Agreement for an additional two years.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315223037533/0001493152-23-037533-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.